DexCom Target of Unusually Large Options Trading (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM) was the recipient of unusually large options trading activity on Thursday. Stock traders purchased 10,495 call options on the stock. This represents an increase of approximately 87% compared to the typical volume of 5,616 call options.

DexCom Stock Down 1.0 %

Shares of DexCom stock traded down $1.33 on Thursday, reaching $136.54. The stock had a trading volume of 1,407,097 shares, compared to its average volume of 2,941,685. The company has a 50 day moving average price of $130.58 and a 200 day moving average price of $117.88. The stock has a market capitalization of $54.07 billion, a P/E ratio of 105.25, a P/E/G ratio of 2.30 and a beta of 1.20. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. DexCom has a 1 year low of $74.75 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The company had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. DexCom’s revenue for the quarter was up 26.9% on a year-over-year basis. During the same period last year, the business earned $0.34 EPS. As a group, equities research analysts forecast that DexCom will post 1.76 EPS for the current year.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several recent analyst reports. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Raymond James raised their target price on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. Royal Bank of Canada assumed coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price on the stock. Citigroup raised their target price on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, UBS Group raised their target price on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $141.40.

Insider Transactions at DexCom

In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Jacob Steven Leach sold 14,639 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the completion of the transaction, the chief operating officer now directly owns 273,913 shares in the company, valued at approximately $36,816,646.33. The disclosure for this sale can be found here. In the last quarter, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is currently owned by insiders.

Institutional Trading of DexCom

Several institutional investors and hedge funds have recently bought and sold shares of DXCM. Founders Financial Securities LLC lifted its stake in DexCom by 7.6% during the 3rd quarter. Founders Financial Securities LLC now owns 3,483 shares of the medical device company’s stock valued at $325,000 after acquiring an additional 246 shares during the period. Exchange Traded Concepts LLC lifted its stake in shares of DexCom by 2.3% in the 3rd quarter. Exchange Traded Concepts LLC now owns 13,338 shares of the medical device company’s stock valued at $1,244,000 after purchasing an additional 306 shares during the period. Caprock Group LLC lifted its stake in shares of DexCom by 2.8% in the 3rd quarter. Caprock Group LLC now owns 17,611 shares of the medical device company’s stock valued at $1,643,000 after purchasing an additional 480 shares during the period. UMB Bank n.a. lifted its stake in shares of DexCom by 7.9% in the 3rd quarter. UMB Bank n.a. now owns 2,796 shares of the medical device company’s stock valued at $261,000 after purchasing an additional 204 shares during the period. Finally, HighMark Wealth Management LLC lifted its stake in shares of DexCom by 7.7% in the 3rd quarter. HighMark Wealth Management LLC now owns 3,209 shares of the medical device company’s stock valued at $299,000 after purchasing an additional 230 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.